Completed
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
NCT00240565
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
- Locations
-
- GSK Investigational Site Calgary, Alberta, Canada
- GSK Investigational Site Edmonton, Alberta, Canada
- GSK Investigational Site Halifax, Nova Scotia, Canada
- GSK Investigational Site Hamilton, Ontario, Canada